Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel/Cisplatin Induction vs Consolidation in Locally Advanced NSCLC
NCT00174772Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2004
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of docetaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sanofi. Primary endpoint: Toxicity and Safety Profile. Started Mar 2004; status: completed.
02
Drugs
docetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00174772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00174772.